MRI Effective for Staging Cancer in Young Patients

Share this content:
MRI Effective for Staging Cancer in Young Patients
MRI Effective for Staging Cancer in Young Patients

(HealthDay News) — A new type of whole-body magnetic resonance imaging (MRI) may allow detection and staging of tumors in children and young adults, without exposure to ionizing radiation, according to research published online Feb. 19 in The Lancet Oncology.

Christopher Klenk, MD, of Stanford University in California, and colleagues performed whole-body diffusion-weighted MRI scans, using the iron supplement ferumoxytol as a contrast agent, and standard clinical 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scans. Participants included 22 children and young adults with malignant lymphomas and sarcomas.

The researchers found that, compared with zero exposure to radiation for the whole-body MRI scans, exposure to ionizing radiation from the PET/CT scans averaged 12.5 mSv.

RELATED: Use of CT Scans in Children: Is it Worth the Risk?

For whole-body diffusion-weighted MRI scans, compared with PET/CT scans, sensitivity was 90.8% versus 93.7%, specificity was 99.5% versus 97.7%, and diagnostic accuracy was 98.3% versus 97.2%.

Tumor staging results showed good agreement between the two imaging modalities.

"Ferumoxytol-enhanced whole-body diffusion-weighted MRI could be an alternative to 18F-FDG PET/CT for staging of children and young adults with cancer that is free of ionising radiation," the researchers wrote. "This new imaging test might help to prevent long-term side-effects from radiographic staging procedures."

In an accompanying editorial, Thomas C. Kwee, MD, PhD, cautioned against immediate application of the study results to clinical practice.

"Although the technical feasibility and potential diagnostic value of using ultrasmall superparamagnetic iron oxide particles in a whole-body diffusion-weighted MRI protocol has been shown in these patients, further work is needed before it can become a clinical alternative to 18F-FDG-PET/CT," Kwee wrote.

One author disclosed financial ties to the biomedical industry.


  1. Klenk C, Gawande R, Uslu L, et al. Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol. 2014; doi:10.1016/S1470-2045(14)70021-X.
  2. Kwee TC. Can whole-body MRI replace 18F-fluorodeoxyglucose PET/CT?. Lancet Oncol. 2014; doi:10.1016/S1470-2045(14)70037-3.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs